NCT02279485View on ClinicalTrials.gov

A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Healthy Subjects
Interventions
DRUG

Perampanel

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02279485 - A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects | Biotech Hunter | Biotech Hunter